RhumbLine Advisers
NGNE icon

RhumbLine Advisers’s Neurogene NGNE Stock Holding History

RhumbLine Advisers’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$280K Buy
13,892
+509
+4% +$9.86K ﹤0.01% 2943
2025
Q4 		$276K Sell
13,383
-1,676
-11% -$41.7K ﹤0.01% 3020
2025
Q3 		$261K Sell
15,059
-266
-2% -$5.34K ﹤0.01% 3085
2025
Q2 		$229K Sell
15,325
-368
-2% -$5.78K ﹤0.01% 3152
2025
Q1 		$184K Sell
15,693
-11
-0.1% -$191 ﹤0.01% 3143
2024
Q4 		$359K Buy
15,704
+1,326
+9% +$49.3K ﹤0.01% 2880
2024
Q3 		$603K Buy
14,378
+889
+7% +$34.5K ﹤0.01% 2577
2024
Q2 		$491K Buy
+13,489
New +$476K ﹤0.01% 2694
2022
Q2 		– Sell
-2,073
Closed -$78K – 3189
2022
Q1 		$78K Sell
2,073
-164
-7% -$9.57K ﹤0.01% 2934
2021
Q4 		$216K Sell
2,237
-30
-1% -$3.65K ﹤0.01% 2817
2021
Q3 		$328K Sell
2,267
-256
-10% -$39.2K ﹤0.01% 2735
2021
Q2 		$466K Buy
2,523
+763
+43% +$169K ﹤0.01% 2595
2021
Q1 		$433K Sell
1,760
-114
-6% -$29.1K ﹤0.01% 2557
2020
Q4 		$529K Buy
1,874
+172
+10% +$42K ﹤0.01% 2422
2020
Q3 		$409K Sell
1,702
-90
-5% -$21.8K ﹤0.01% 2380
2020
Q2 		$595K Buy
+1,792
New +$467K ﹤0.01% 2266

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

RhumbLine Advisers's NGNE Position: Q1 2026 in Review

RhumbLine Advisers increased its Neurogene (NGNE) stake by 3.8% in Q1 2026, buying an estimated $9.86K and bringing the position to 13,892 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2943.

RhumbLine Advisers first reported a position in NGNE in Q2 2020 and has held it in 16 quarters since. The position peaked at $603K in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • RhumbLine Advisers held 13,892 shares of Neurogene worth $280K as of Q1 2026.
  • RhumbLine Advisers bought 509 Neurogene shares in Q1 2026, an estimated $9.86K.
  • Neurogene made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2943 holding.
  • RhumbLine Advisers first reported a position in Neurogene in Q2 2020 and has held it in 16 quarters since.
  • RhumbLine Advisers's Neurogene position peaked at $603K in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.